Search

Your search keyword '"Liberal, R"' showing total 217 results
Start Over Author "Liberal, R"
217 results on '"Liberal, R"'

1. Incidence and predictors of hepatocellular carcinoma in patients with autoimmune hepatitis

Author

van Gerven, N., van Erpecum, K., Ouden, J den, Brouwer, J., Vrolijk, J., Gevers, T.J., Drenth, J., Guichelaar, M., Bouma, G., Schreuder, T.C.M.A., van der Wouden, E.J., Baak, L.C., Stadhouders, P., Klemt-Kropp, M., Verhagen, M., Bhalla, A., Kuijvenhoven, J., Almasio, P., Alvarez, F., Andrade, R., Arikan, C., Assis, D., Bardou-Jacquet, E., Biewenga, M., Cancado, E., Cazzagon, N., Chazouillères, O., Colloredo, G., Cuarterolo, M., Dalekos, G., Debray, D., Robles-Díaz, M., Dyson, J., Efe, C., Engel, B., Ferri, S., Fontana, R., Gatselis, N., Gerussi, A., Halilbasic, E., Halliday, N., Heneghan, M., Hirschfield, G., van Hoek, B., Hørby Jørgensen, M., Indolfini, G., Iorio, R., Invernizzi, P., Jeong, S., Jones, D., Kelly, D., Kerkar, N., Lacaille, F., Lammert, C., Leggett, B., Lenzi, M., Levy, C., Liberal, R., Lleo, A., Lohse, A., Lopez, S. Ines, de Martin, E., McLin, V., Mieli-Vergani, G., Milkiewicz, P., Mohan, N., Muratori, L., Nebbia, G., van Nieuwkerk, C., Oo, Y., Ortega, A., Páres, A., Pop, T., Pratt, D., Purnak, T., Ranucci, G., Rushbrook, S., Schramm, C., Stättermayer, A., Swain, M., Tanaka, A., Taubert, R., Terrabuio, D., Terziroli, B., Trauner, M., Valentino, P., van den Brand, F., Vergani, D., Villamil, A., Wahlin, S., Ytting, H., Zachou, K., Zeniya, M., Colapietro, Francesca, Maisonneuve, Patrick, Lytvyak, Ellina, Beuers, Ulrich, Verdonk, Robert C., van der Meer, Adriaan J., van Hoek, Bart, Kuiken, Sjoerd D., Brouwer, Johannes T., Muratori, Paolo, Aghemo, Alessio, Carella, Francesco, van den Berg, Ad P., Zachou, Kalliopi, Dalekos, George N., Di Zeo-Sánchez, Daniel E., Robles, Mercedes, Andrade, Raul J., Montano-Loza, Aldo J., van den Brand, Floris F., Slooter, Charlotte D., Macedo, Guilherme, Liberal, Rodrigo, de Boer, Ynto S., and Lleo, Ana

Published
2024
Full Text
View/download PDF

2. Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group

Author

Almasio, P., Alvarez, F., Andrade, R., Arikan, C., Assis, D., Bardou-Jacquet, E., Biewenga, M., Cancado, E., Cazzagon, N., Chazouillères, O., Colloredo, G., Cuarterolo, M., Dalekos, G., Debray, D., Robles-Díaz, M., Drenth, J., Dyson, J., Efe, C., Engel, B., Ferri, S., Fontana, R., Gatselis, N., Gerussi, A., Halilbasic, E., Halliday, N., Heneghan, M., Hirschfield, G., van Hoek, B., Hørby Jørgensen, M., Indolfini, G., Iorio, R., Jeong, S., Jones, D., Kelly, D., Kerkar, N., Lacaille, F., Lammert, C., Leggett, B., Lenzi, M., Levy, C., Liberal, R., Lleo, A., Lohse, A., Ines Lopez, S., de Martin, E., McLin, V., Mieli-Vergani, G., Milkiewicz, P., Mohan, N., Muratori, L., Nebbia, G., van Nieuwkerk, C., Oo, Y., Ortega, A., Páres, A., Pop, T., Pratt, D., Purnak, T., Ranucci, G., Rushbrook, S., Schramm, C., Stättermayer, A., Swain, M., Tanaka, A., Taubert, R., Terrabuio, D., Terziroli, B., Trauner, M., Valentino, P., van den Brand, F., Villamil, A., Wahlin, S., Ytting, H., Zachou, K., Zeniya, M., Pape, Simon, Snijders, Romée J.A.L.M., Gevers, Tom J.G., Chazouilleres, Oliver, Dalekos, George N., Hirschfield, Gideon M., Lenzi, Marco, Trauner, Michael, Manns, Michael P., Vierling, John M., Montano-Loza, Aldo J., Lohse, Ansgar W., Schramm, Christoph, Drenth, Joost P.H., and Heneghan, Michael A.

Published
2022
Full Text
View/download PDF

3. Lack of complete biochemical response in autoimmune hepatitis leads to adverse outcome: First report of the IAIHG retrospective registry

Author

Slooter, C.D., Brand, F.F. van den, Lleo, A., Colapietro, F., Lenzi, M., Muratori, P., Kerkar, N., Dalekos, G.N., Zachou, K., Lucena, M.I., Robles-Díaz, M., Zeo-Sánchez, D.E. Di, Andrade, R.J., Montano-Loza, A.J., Lytvyak, E., Lissenberg-Witte, Birgit I., Maisonneuve, P., Bouma, G., Macedo, G., Drenth, J.P.H., Liberal, R., Boer, Y.S. de, Slooter, C.D., Brand, F.F. van den, Lleo, A., Colapietro, F., Lenzi, M., Muratori, P., Kerkar, N., Dalekos, G.N., Zachou, K., Lucena, M.I., Robles-Díaz, M., Zeo-Sánchez, D.E. Di, Andrade, R.J., Montano-Loza, A.J., Lytvyak, E., Lissenberg-Witte, Birgit I., Maisonneuve, P., Bouma, G., Macedo, G., Drenth, J.P.H., Liberal, R., and Boer, Y.S. de

Abstract

Contains fulltext : 305452.pdf (Publisher’s version ) (Closed access), BACKGROUND AND AIMS: The International Autoimmune Hepatitis Group retrospective registry (IAIHG-RR) is a web-based platform with subjects enrolled with a clinical diagnosis of autoimmune hepatitis (AIH). As prognostic factor studies with enough power are scarce, this study aimed to ascertain data quality and identify prognostic factors in the IAIHG-RR cohort. METHODS: This retrospective, observational, multicenter study included all patients with a clinical diagnosis of AIH from the IAIHG-RR. The quality assessment consisted of external validation of completeness and consistency for 29 predefined variables. Cox regression was used to identify risk factors for liver-related death and liver transplantation (LT). RESULTS: This analysis included 2559 patients across 7 countries. In 1700 patients, follow-up was available, with a completeness of individual data of 90% (range: 30-100). During a median follow-up period of 10 (range: 0-49) years, there were 229 deaths, of which 116 were liver-related, and 143 patients underwent LT. Non-White ethnicity (HR 4.1 95% CI: 2.3-7.1), cirrhosis (HR 3.5 95% CI: 2.3-5.5), variant syndrome with primary sclerosing cholangitis (PSC) (HR 3.1 95% CI: 1.6-6.2), and lack of complete biochemical response within 6 months (HR 5.7 95% CI: 3.4-9.6) were independent prognostic factors. CONCLUSIONS: The IAIHG-RR represents the world's largest AIH cohort with moderate-to-good data quality and a relevant number of liver-related events. The registry is a suitable platform for patient selection in future studies. Lack of complete biochemical response to treatment, non-White ethnicity, cirrhosis, and PSC-AIH were associated with liver-related death and LT.

Published
2024

4. Incidence and predictors of hepatocellular carcinoma in patients with autoimmune hepatitis

Author

Colapietro, Francesca, primary, Maisonneuve, Patrick, additional, Lytvyak, Ellina, additional, Beuers, Ulrich, additional, Verdonk, Robert C., additional, van der Meer, Adriaan J., additional, van Hoek, Bart, additional, Kuiken, Sjoerd D., additional, Brouwer, Johannes T., additional, Muratori, Paolo, additional, Aghemo, Alessio, additional, Carella, Francesco, additional, van den Berg, Ad P., additional, Zachou, Kalliopi, additional, Dalekos, George N., additional, Di Zeo-Sánchez, Daniel E., additional, Robles, Mercedes, additional, Andrade, Raul J., additional, Montano-Loza, Aldo J., additional, van den Brand, Floris F., additional, Slooter, Charlotte D., additional, Macedo, Guilherme, additional, Liberal, Rodrigo, additional, de Boer, Ynto S., additional, Lleo, Ana, additional, van Gerven, N., additional, van Erpecum, K., additional, Ouden, J den, additional, Brouwer, J., additional, Vrolijk, J., additional, Gevers, T.J., additional, Drenth, J., additional, Guichelaar, M., additional, Bouma, G., additional, Schreuder, T.C.M.A., additional, van der Wouden, E.J., additional, Baak, L.C., additional, Stadhouders, P., additional, Klemt-Kropp, M., additional, Verhagen, M., additional, Bhalla, A., additional, Kuijvenhoven, J., additional, Almasio, P., additional, Alvarez, F., additional, Andrade, R., additional, Arikan, C., additional, Assis, D., additional, Bardou-Jacquet, E., additional, Biewenga, M., additional, Cancado, E., additional, Cazzagon, N., additional, Chazouillères, O., additional, Colloredo, G., additional, Cuarterolo, M., additional, Dalekos, G., additional, Debray, D., additional, Robles-Díaz, M., additional, Dyson, J., additional, Efe, C., additional, Engel, B., additional, Ferri, S., additional, Fontana, R., additional, Gatselis, N., additional, Gerussi, A., additional, Halilbasic, E., additional, Halliday, N., additional, Heneghan, M., additional, Hirschfield, G., additional, van Hoek, B., additional, Hørby Jørgensen, M., additional, Indolfini, G., additional, Iorio, R., additional, Invernizzi, P., additional, Jeong, S., additional, Jones, D., additional, Kelly, D., additional, Kerkar, N., additional, Lacaille, F., additional, Lammert, C., additional, Leggett, B., additional, Lenzi, M., additional, Levy, C., additional, Liberal, R., additional, Lleo, A., additional, Lohse, A., additional, Lopez, S. Ines, additional, de Martin, E., additional, McLin, V., additional, Mieli-Vergani, G., additional, Milkiewicz, P., additional, Mohan, N., additional, Muratori, L., additional, Nebbia, G., additional, van Nieuwkerk, C., additional, Oo, Y., additional, Ortega, A., additional, Páres, A., additional, Pop, T., additional, Pratt, D., additional, Purnak, T., additional, Ranucci, G., additional, Rushbrook, S., additional, Schramm, C., additional, Stättermayer, A., additional, Swain, M., additional, Tanaka, A., additional, Taubert, R., additional, Terrabuio, D., additional, Terziroli, B., additional, Trauner, M., additional, Valentino, P., additional, van den Brand, F., additional, Vergani, D., additional, Villamil, A., additional, Wahlin, S., additional, Ytting, H., additional, Zachou, K., additional, and Zeniya, M., additional

Published
2023
Full Text
View/download PDF

6. Liver injury after SARS-CoV-2 vaccination: Features of immune-mediated hepatitis, role of corticosteroid therapy and outcome

Author

Efe, C, Kulkarni, A, Terziroli Beretta-Piccoli, B, Magro, B, Friedrich Stattermayer, A, Cengiz, M, Clayton-Chubb, D, Lammert, C, Bernsmeier, C, Gul, O, la Tijera, F, Anders, M, Lytvyak, E, Akin, M, Purnak, T, Liberal, R, Peralta, M, Ebik, B, Duman, S, Demir, N, Balaban, Y, Urzua, A, Contreras, F, Venturelli, M, Bilgic, Y, Medina, A, Girala, M, Gunsar, F, Londono, M, Androutsakos, T, Kisch, A, Yurci, A, Guzelbult, F, Cagin, Y, Avci, E, Guzelbulut, M, Dindar-Demiray, E, Harputluoglu, M, Kumar, R, Satapathy, S, Mendizabal, M, Silva, M, Fagiuoli, S, Roberts, S, Soylu, N, Idilman, R, Yoshida, E, Montano-Loza, A, Dalekos, G, Ridruejo, E, Schiano, T, Wahlin, S, Efe C., Kulkarni A. V., Terziroli Beretta-Piccoli B., Magro B., Friedrich Stattermayer A., Cengiz M., Clayton-Chubb D., Lammert C., Bernsmeier C., Gul O., la Tijera F. H. -D., Anders M., Lytvyak E., Akin M., Purnak T., Liberal R., Peralta M., Ebik B., Duman S., Demir N., Balaban Y., Urzua A., Contreras F., Venturelli M. G., Bilgic Y., Medina A., Girala M., Gunsar F., Londono M. -C., Androutsakos T., Kisch A., Yurci A., Guzelbult F., Cagin Y. F., Avci E., Guzelbulut M., Dindar-Demiray E. K., Harputluoglu M., Kumar R., Satapathy S. K., Mendizabal M., Silva M., Fagiuoli S., Roberts S. K., Soylu N. K., Idilman R., Yoshida E. M., Montano-Loza A. J., Dalekos G. N., Ridruejo E., Schiano T. D., Wahlin S., Efe, C, Kulkarni, A, Terziroli Beretta-Piccoli, B, Magro, B, Friedrich Stattermayer, A, Cengiz, M, Clayton-Chubb, D, Lammert, C, Bernsmeier, C, Gul, O, la Tijera, F, Anders, M, Lytvyak, E, Akin, M, Purnak, T, Liberal, R, Peralta, M, Ebik, B, Duman, S, Demir, N, Balaban, Y, Urzua, A, Contreras, F, Venturelli, M, Bilgic, Y, Medina, A, Girala, M, Gunsar, F, Londono, M, Androutsakos, T, Kisch, A, Yurci, A, Guzelbult, F, Cagin, Y, Avci, E, Guzelbulut, M, Dindar-Demiray, E, Harputluoglu, M, Kumar, R, Satapathy, S, Mendizabal, M, Silva, M, Fagiuoli, S, Roberts, S, Soylu, N, Idilman, R, Yoshida, E, Montano-Loza, A, Dalekos, G, Ridruejo, E, Schiano, T, Wahlin, S, Efe C., Kulkarni A. V., Terziroli Beretta-Piccoli B., Magro B., Friedrich Stattermayer A., Cengiz M., Clayton-Chubb D., Lammert C., Bernsmeier C., Gul O., la Tijera F. H. -D., Anders M., Lytvyak E., Akin M., Purnak T., Liberal R., Peralta M., Ebik B., Duman S., Demir N., Balaban Y., Urzua A., Contreras F., Venturelli M. G., Bilgic Y., Medina A., Girala M., Gunsar F., Londono M. -C., Androutsakos T., Kisch A., Yurci A., Guzelbult F., Cagin Y. F., Avci E., Guzelbulut M., Dindar-Demiray E. K., Harputluoglu M., Kumar R., Satapathy S. K., Mendizabal M., Silva M., Fagiuoli S., Roberts S. K., Soylu N. K., Idilman R., Yoshida E. M., Montano-Loza A. J., Dalekos G. N., Ridruejo E., Schiano T. D., and Wahlin S.

Abstract

Background and Aims: A few case reports of autoimmune hepatitis–like liver injury have been reported after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. We evaluated clinical features, treatment response and outcomes of liver injury following SARS-CoV-2 vaccination in a large case series. Approach and Results: We collected data from cases in 18 countries. The type of liver injury was assessed with the R-value. The study population was categorized according to features of immune-mediated hepatitis (positive autoantibodies and elevated immunoglobulin G levels) and corticosteroid therapy for the liver injury. We identified 87 patients (63%, female), median age 48 (range: 18–79) years at presentation. Liver injury was diagnosed a median 15 (range: 3–65) days after vaccination. Fifty-one cases (59%) were attributed to the Pfizer-BioNTech (BNT162b2) vaccine, 20 (23%) cases to the Oxford-AstraZeneca (ChAdOX1 nCoV-19) vaccine and 16 (18%) cases to the Moderna (mRNA-1273) vaccine. The liver injury was predominantly hepatocellular (84%) and 57% of patients showed features of immune-mediated hepatitis. Corticosteroids were given to 46 (53%) patients, more often for grade 3–4 liver injury than for grade 1–2 liver injury (88.9% vs. 43.5%, p = 0.001) and more often for patients with than without immune-mediated hepatitis (71.1% vs. 38.2%, p = 0.003). All patients showed resolution of liver injury except for one man (1.1%) who developed liver failure and underwent liver transplantation. Steroid therapy was withdrawn during the observation period in 12 (26%) patients after complete biochemical resolution. None had a relapse during follow-up. Conclusions: SARS-CoV-2 vaccination can be associated with liver injury. Corticosteroid therapy may be beneficial in those with immune-mediated features or severe hepatitis. Outcome was generally favorable, but vaccine-associated liver injury led to fulminant liver failure in one patient.

Published
2022

7. Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group

Author

Pape, S, Snijders, R, Gevers, T, Chazouilleres, O, Dalekos, G, Hirschfield, G, Lenzi, M, Trauner, M, Manns, M, Vierling, J, Montano-Loza, A, Lohse, A, Schramm, C, Drenth, J, Heneghan, M, Almasio, P, Alvarez, F, Andrade, R, Arikan, C, Assis, D, Bardou-Jacquet, E, Biewenga, M, Cancado, E, Cazzagon, N, Colloredo, G, Cuarterolo, M, Debray, D, Robles-Diaz, M, Dyson, J, Efe, C, Engel, B, Ferri, S, Fontana, R, Gatselis, N, Gerussi, A, Halilbasic, E, Halliday, N, van Hoek, B, Horby Jorgensen, M, Indolfini, G, Iorio, R, Jeong, S, Jones, D, Kelly, D, Kerkar, N, Lacaille, F, Lammert, C, Leggett, B, Levy, C, Liberal, R, Lleo, A, Ines Lopez, S, de Martin, E, Mclin, V, Mieli-Vergani, G, Milkiewicz, P, Mohan, N, Muratori, L, Nebbia, G, van Nieuwkerk, C, Oo, Y, Ortega, A, Pares, A, Pop, T, Pratt, D, Purnak, T, Ranucci, G, Rushbrook, S, Stattermayer, A, Swain, M, Tanaka, A, Taubert, R, Terrabuio, D, Terziroli, B, Valentino, P, van den Brand, F, Villamil, A, Wahlin, S, Ytting, H, Zachou, K, Zeniya, M, Pape S., Snijders R. J. A. L. M., Gevers T. J. G., Chazouilleres O., Dalekos G. N., Hirschfield G. M., Lenzi M., Trauner M., Manns M. P., Vierling J. M., Montano-Loza A. J., Lohse A. W., Schramm C., Drenth J. P. H., Heneghan M. A., Almasio P., Alvarez F., Andrade R., Arikan C., Assis D., Bardou-Jacquet E., Biewenga M., Cancado E., Cazzagon N., Colloredo G., Cuarterolo M., Dalekos G., Debray D., Robles-Diaz M., Drenth J., Dyson J., Efe C., Engel B., Ferri S., Fontana R., Gatselis N., Gerussi A., Halilbasic E., Halliday N., Heneghan M., Hirschfield G., van Hoek B., Horby Jorgensen M., Indolfini G., Iorio R., Jeong S., Jones D., Kelly D., Kerkar N., Lacaille F., Lammert C., Leggett B., Levy C., Liberal R., Lleo A., Lohse A., Ines Lopez S., de Martin E., McLin V., Mieli-Vergani G., Milkiewicz P., Mohan N., Muratori L., Nebbia G., van Nieuwkerk C., Oo Y., Ortega A., Pares A., Pop T., Pratt D., Purnak T., Ranucci G., Rushbrook S., Stattermayer A., Swain M., Tanaka A., Taubert R., Terrabuio D., Terziroli B., Valentino P., van den Brand F., Villamil A., Wahlin S., Ytting H., Zachou K., Zeniya M., Pape, S, Snijders, R, Gevers, T, Chazouilleres, O, Dalekos, G, Hirschfield, G, Lenzi, M, Trauner, M, Manns, M, Vierling, J, Montano-Loza, A, Lohse, A, Schramm, C, Drenth, J, Heneghan, M, Almasio, P, Alvarez, F, Andrade, R, Arikan, C, Assis, D, Bardou-Jacquet, E, Biewenga, M, Cancado, E, Cazzagon, N, Colloredo, G, Cuarterolo, M, Debray, D, Robles-Diaz, M, Dyson, J, Efe, C, Engel, B, Ferri, S, Fontana, R, Gatselis, N, Gerussi, A, Halilbasic, E, Halliday, N, van Hoek, B, Horby Jorgensen, M, Indolfini, G, Iorio, R, Jeong, S, Jones, D, Kelly, D, Kerkar, N, Lacaille, F, Lammert, C, Leggett, B, Levy, C, Liberal, R, Lleo, A, Ines Lopez, S, de Martin, E, Mclin, V, Mieli-Vergani, G, Milkiewicz, P, Mohan, N, Muratori, L, Nebbia, G, van Nieuwkerk, C, Oo, Y, Ortega, A, Pares, A, Pop, T, Pratt, D, Purnak, T, Ranucci, G, Rushbrook, S, Stattermayer, A, Swain, M, Tanaka, A, Taubert, R, Terrabuio, D, Terziroli, B, Valentino, P, van den Brand, F, Villamil, A, Wahlin, S, Ytting, H, Zachou, K, Zeniya, M, Pape S., Snijders R. J. A. L. M., Gevers T. J. G., Chazouilleres O., Dalekos G. N., Hirschfield G. M., Lenzi M., Trauner M., Manns M. P., Vierling J. M., Montano-Loza A. J., Lohse A. W., Schramm C., Drenth J. P. H., Heneghan M. A., Almasio P., Alvarez F., Andrade R., Arikan C., Assis D., Bardou-Jacquet E., Biewenga M., Cancado E., Cazzagon N., Colloredo G., Cuarterolo M., Dalekos G., Debray D., Robles-Diaz M., Drenth J., Dyson J., Efe C., Engel B., Ferri S., Fontana R., Gatselis N., Gerussi A., Halilbasic E., Halliday N., Heneghan M., Hirschfield G., van Hoek B., Horby Jorgensen M., Indolfini G., Iorio R., Jeong S., Jones D., Kelly D., Kerkar N., Lacaille F., Lammert C., Leggett B., Levy C., Liberal R., Lleo A., Lohse A., Ines Lopez S., de Martin E., McLin V., Mieli-Vergani G., Milkiewicz P., Mohan N., Muratori L., Nebbia G., van Nieuwkerk C., Oo Y., Ortega A., Pares A., Pop T., Pratt D., Purnak T., Ranucci G., Rushbrook S., Stattermayer A., Swain M., Tanaka A., Taubert R., Terrabuio D., Terziroli B., Valentino P., van den Brand F., Villamil A., Wahlin S., Ytting H., Zachou K., and Zeniya M.

Abstract

Background & Aims: Autoimmune hepatitis (AIH) has been well characterised and codified through the development of diagnostic criteria. These criteria have been adapted and simplified and are widely used in clinical practice. However, there is a need to update and precisely define the criteria for both treatment response and treatment. Methods: A systematic review was performed and a modified Delphi consensus process was used to identify and redefine the response criteria in autoimmune hepatitis. Results: The consensus process initiated by the International Autoimmune Hepatitis Group proposes that the term ‘complete biochemical response’ defined as ‘normalization of serum transaminases and IgG below the upper limit of normal’ be adopted to include a time point at 6 months after initiation of treatment. An insufficient response by 6 months was a failure to meet the above definition. Non-response was defined as ‘<50% decrease of serum transaminases within 4 weeks after initiation of treatment’. Remission is defined as liver histology with a Hepatitis Activity Index <4/18. Intolerance to treatment was agreed to stand for ‘any adverse event possibly related to treatment leading to potential drug discontinuation’. Conclusions: These definitions provide a simple and reproducible framework to define treatment response and non-response, irrespective of the therapeutic intervention. A consensus on endpoints is urgently required to set a global standard for the reporting of study results and to enable inter-study comparisons. Future prospective database studies are needed to validate these endpoints. Lay summary: Consensus among international experts on response criteria and endpoints in autoimmune hepatitis is lacking. A consensus on endpoints is urgently required to set a global standard for the reporting of study results and to enable the comparison of results between clinical trials. Therefore, the International Autoimmune Hepatitis Group (IAIHG) herein presents

Published
2022

8. Incidence and predictors of hepatocellular carcinoma in autoimmune hepatitis: A multicenter international study

Author

Colapietro, F., primary, Maisonneuve, P., additional, Lytvyak, E., additional, Beuers, U., additional, Verdonk, R., additional, van der Meer, A., additional, van Hoek, B., additional, Kuiken, S.J., additional, Brouwer, H., additional, van der Wouden, E.J., additional, Muratori, P., additional, Aghemo, A., additional, van den Berg, A., additional, Dalekos, G. N, additional, Robles, M., additional, Andrade, R.J., additional, Montano-Loza, A.J., additional, van den Brand, F.F., additional, Slooter, C.D., additional, Macedo, G., additional, Liberal, R., additional, de Boer, Y., additional, and Lleo, A., additional

Published
2023
Full Text
View/download PDF

12. Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group

Author

Pape, Simon, primary, Snijders, Romée J.A.L.M., additional, Gevers, Tom J.G., additional, Chazouilleres, Oliver, additional, Dalekos, George N., additional, Hirschfield, Gideon M., additional, Lenzi, Marco, additional, Trauner, Michael, additional, Manns, Michael P., additional, Vierling, John M., additional, Montano-Loza, Aldo J., additional, Lohse, Ansgar W., additional, Schramm, Christoph, additional, Drenth, Joost P.H., additional, Heneghan, Michael A., additional, Almasio, P., additional, Alvarez, F., additional, Andrade, R., additional, Arikan, C., additional, Assis, D., additional, Bardou-Jacquet, E., additional, Biewenga, M., additional, Cancado, E., additional, Cazzagon, N., additional, Chazouillères, O., additional, Colloredo, G., additional, Cuarterolo, M., additional, Dalekos, G., additional, Debray, D., additional, Robles-Díaz, M., additional, Drenth, J., additional, Dyson, J., additional, Efe, C., additional, Engel, B., additional, Ferri, S., additional, Fontana, R., additional, Gatselis, N., additional, Gerussi, A., additional, Halilbasic, E., additional, Halliday, N., additional, Heneghan, M., additional, Hirschfield, G., additional, van Hoek, B., additional, Hørby Jørgensen, M., additional, Indolfini, G., additional, Iorio, R., additional, Jeong, S., additional, Jones, D., additional, Kelly, D., additional, Kerkar, N., additional, Lacaille, F., additional, Lammert, C., additional, Leggett, B., additional, Lenzi, M., additional, Levy, C., additional, Liberal, R., additional, Lleo, A., additional, Lohse, A., additional, Ines Lopez, S., additional, de Martin, E., additional, McLin, V., additional, Mieli-Vergani, G., additional, Milkiewicz, P., additional, Mohan, N., additional, Muratori, L., additional, Nebbia, G., additional, van Nieuwkerk, C., additional, Oo, Y., additional, Ortega, A., additional, Páres, A., additional, Pop, T., additional, Pratt, D., additional, Purnak, T., additional, Ranucci, G., additional, Rushbrook, S., additional, Schramm, C., additional, Stättermayer, A., additional, Swain, M., additional, Tanaka, A., additional, Taubert, R., additional, Terrabuio, D., additional, Terziroli, B., additional, Trauner, M., additional, Valentino, P., additional, van den Brand, F., additional, Villamil, A., additional, Wahlin, S., additional, Ytting, H., additional, Zachou, K., additional, and Zeniya, M., additional

Published
2022
Full Text
View/download PDF

14. Association Between Black Race and Presentation and Liver-Related Outcomes of Patients With Autoimmune Hepatitis

Author

de Boer, Y, Gerussi, A, van den Brand, F, Wong, G, Halliday, N, Liberal, R, Drenth, J, Thorburn, D, Bouma, G, van Gerven, N, Beuers, U, van Erpecum, K, van Buuren, H, den Ouden, J, Brouwer, J, Vrolijk, J, Verdonk, R, van Hoek, B, Koek, G, Guichelaar, M, Bloemena, E, van Nieuwkerk, C, Schreuder, T, van der Wouden, E, van Meyel, J, Baak, L, Stadhouders, P, Klemt-Kropp, M, Verhagen, M, Bhalla, A, Kuijvenhoven, J, Heneghan, M, de Boer Y. S., Gerussi A., van den Brand F. F., Wong G. -W., Halliday N., Liberal R., Drenth J. P. H., Thorburn D., Bouma G., van Gerven N. M., Beuers U., van Erpecum K. J., van Buuren H. R., den Ouden J. W., Brouwer J. T., Vrolijk J. M., Verdonk R. C., van Hoek B., Koek G. H., Guichelaar M. M. J., Bloemena E., van Nieuwkerk C. M. J., Schreuder T. C. M. A., van der Wouden E. J., van Meyel J. J. M., Baak L. C., Stadhouders P. H. G. M., Klemt-Kropp M., Verhagen M. A. M. T., Bhalla A., Kuijvenhoven J. P., Heneghan M. A., de Boer, Y, Gerussi, A, van den Brand, F, Wong, G, Halliday, N, Liberal, R, Drenth, J, Thorburn, D, Bouma, G, van Gerven, N, Beuers, U, van Erpecum, K, van Buuren, H, den Ouden, J, Brouwer, J, Vrolijk, J, Verdonk, R, van Hoek, B, Koek, G, Guichelaar, M, Bloemena, E, van Nieuwkerk, C, Schreuder, T, van der Wouden, E, van Meyel, J, Baak, L, Stadhouders, P, Klemt-Kropp, M, Verhagen, M, Bhalla, A, Kuijvenhoven, J, Heneghan, M, de Boer Y. S., Gerussi A., van den Brand F. F., Wong G. -W., Halliday N., Liberal R., Drenth J. P. H., Thorburn D., Bouma G., van Gerven N. M., Beuers U., van Erpecum K. J., van Buuren H. R., den Ouden J. W., Brouwer J. T., Vrolijk J. M., Verdonk R. C., van Hoek B., Koek G. H., Guichelaar M. M. J., Bloemena E., van Nieuwkerk C. M. J., Schreuder T. C. M. A., van der Wouden E. J., van Meyel J. J. M., Baak L. C., Stadhouders P. H. G. M., Klemt-Kropp M., Verhagen M. A. M. T., Bhalla A., Kuijvenhoven J. P., and Heneghan M. A.

Abstract

Introduction & Aims: Small studies have found that black patients with autoimmune hepatitis (AIH) present with more aggressive disease. We aimed to characterize the presentation and outcome in black and white patients with AIH. Methods: We performed a retrospective study, collecting information from databases of patients with AIH attending the Institute of Liver studies at King's College Hospital, London (1971–October 2015, the Royal Free Hospital, London (1982 through December 2016) and the multicenter Dutch Autoimmune Hepatitis Study Group cohort (2006–August 2016). We identified 88 black patients with AIH and we compared their clinical characteristics and outcomes to 897 white patients with AIH. Results: Black patients presented at a younger age (median 38 years vs 45 years) (P =.007), had higher IgG levels (mean 31.0 mg/dL vs 27.5 mg/dL) (P =.04), but there were no significant differences between groups in auto-antibody profiles, International AIH Group scores, or sex distribution of disease. A higher proportion of black patients had systemic lupus erythematosus (10%) than white patients (2%) (P ≤.001). There was no significant difference in proportions of patients with a response to standard therapy (86% for black patients vs 91% for white patients; P =.20) or in rate of relapse (57% vs 50%; P =.3). Despite this, black patients had an increased risk of liver transplantation and liver-related death (hazard ratio 2.4, 95% confidence interval, 1.4–4.0; P <.001). Overall mortality was similar between the two groups. Conclusion: In a comparison of black and white patients with AIH in Europe, we found that black patients present at a younger age, have higher levels of IgG levels, and a greater proportion have SLE. We also found black patients to have a greater risk of liver transplantation and liver-related mortality, indicating more aggressive disease.

Published
2019

22. Characteristics associated with non-response to ursodeoxycholic acid in primary biliary cholangitis

Author

Dias, T., primary, Santos, A., additional, Carvalho, J., additional, Bento-Miranda, M., additional, Sant’anna, M., additional, Calinas, F., additional, Loureiro, R., additional, Martins, A., additional, Alexandrino, G., additional, Cotrim, I., additional, Martins, C., additional, Presa, J., additional, Mesquita, M., additional, Nunes, J., additional, Ferreira, A., additional, Horta e Vale, A., additional, Alves, A.L.C., additional, Pedroto, I., additional, Maia, L., additional, Banhudo, A., additional, Mocanu, I., additional, Laranjo, A.M., additional, Lopes, S., additional, Liberal, R., additional, Fonseca, C., additional, Oliveira, J., additional, Gomes, M., additional, and Cortez-Pinto, H., additional

Published
2018
Full Text
View/download PDF

23. Role of alpha-1 antitrypsin genotypes in the progression of adult liver disease

Author

Pereira, V., primary, Gaspar, R., additional, Simões, C., additional, Maia, L., additional, Costa, D., additional, Carvão, J., additional, Oliveira, A., additional, Serrão, G., additional, Jesus, V., additional, Sucena, M.C., additional, Santos, C., additional, Gomes, J., additional, Lages, J., additional, Abreu, I., additional, Freitas, S., additional, Carvalhana, S., additional, Mandorfer, M., additional, Cortez-Pinto, H., additional, Macedo, G., additional, Trauner, M., additional, Liberal, R., additional, and Jasmins, L., additional

Published
2018
Full Text
View/download PDF

25. Expert clinical management of autoimmune hepatitis in the real world

Author

Liberal, R, de Boer, Y, Andrade, R, Bouma, G, Dalekos, G, Floreani, A, Gleeson, D, Hirschfield, G, Invernizzi, P, Lenzi, M, Lohse, A, Macedo, G, Milkiewicz, P, Terziroli, B, van Hoek, B, Vierling, J, Heneghan, M, INVERNIZZI, PIETRO, Heneghan, M., Liberal, R, de Boer, Y, Andrade, R, Bouma, G, Dalekos, G, Floreani, A, Gleeson, D, Hirschfield, G, Invernizzi, P, Lenzi, M, Lohse, A, Macedo, G, Milkiewicz, P, Terziroli, B, van Hoek, B, Vierling, J, Heneghan, M, INVERNIZZI, PIETRO, and Heneghan, M.

Abstract

Background: High-quality data on the management of autoimmune hepatitis (AIH) are scarce. Despite published guidelines, management of AIH is still expert based rather than evidence based. Aim: To survey expert hepatologists, asking each to describe their practices in the management of patients with AIH. Methods: A survey questionnaire was distributed to members of the International AIH Group. The questionnaire consisted of four clinical scenarios on different presentations of AIH. Results: Sixty surveys were sent, out of which 37 were returned. None reported budesonide as a first line induction agent for the acute presentation of AIH. Five (14%) participants reported using thiopurine S-methyltransferase measurements before commencement of thiopurine maintenance therapy. Thirteen (35%) routinely perform liver biopsy at 2 years of biochemical remission. If histological inflammatory activity is absent, four (11%) participants reduced azathioprine, whereas 10 (27%) attempted withdrawal altogether. Regarding the management of difficult-to-treat patients, mycophenolate mofetil is the most widely used second-line agent (n = ~450 in 28 centres), whereas tacrolimus (n = ~115 in 21 centres) and ciclosporin (n = ~112 in 18 centres) are less often reported. One centre reported considerable experience with infliximab, while rescue therapy with rituximab has been tried in seven centres. Conclusions: There is a wide variation in the management of patients with autoimmune hepatitis even among the most expert in the field. Although good quality evidence is lacking, there is considerable experience with second-line therapies. Future prospective studies should address these issues, so that we move from an expert- to an evidence- and personalised-based care in autoimmune hepatitis.

Published
2017

30. SAT-062 - Characteristics associated with non-response to ursodeoxycholic acid in primary biliary cholangitis

Author

Dias, T., Santos, A., Carvalho, J., Bento-Miranda, M., Sant’anna, M., Calinas, F., Loureiro, R., Martins, A., Alexandrino, G., Cotrim, I., Martins, C., Presa, J., Mesquita, M., Nunes, J., Ferreira, A., Horta e Vale, A., Alves, A.L.C., Pedroto, I., Maia, L., Banhudo, A., Mocanu, I., Laranjo, A.M., Lopes, S., Liberal, R., Fonseca, C., Oliveira, J., Gomes, M., and Cortez-Pinto, H.

Published
2018
Full Text
View/download PDF

32. Clinical Management of Autoimmune Hepatitis in the Real World

Author

Liberal, R., primary, de Boer, Y., additional, Andrade, R.J., additional, Bouma, G., additional, Dalekos, G.N., additional, Floreani, A., additional, Gleeson, D., additional, Hirschfield, G., additional, Invernizzi, P., additional, Lenzi, M., additional, Lohse, A., additional, Macedo, G., additional, Milkiewicz, P., additional, Terziroli, B., additional, van Hoek, B., additional, Vierling, J., additional, and Heneghan, M.A., additional

Published
2016
Full Text
View/download PDF

40. Real-world management of juvenile autoimmune liver disease

Author

de Boer, Y S, Liberal, R, Vergani, D, and Mieli-Vergani, G

Abstract

Background and aims Juvenile autoimmune liver disease (JAILD) includes paediatric forms of autoimmune hepatitis (AIH) and autoimmune sclerosing cholangitis (ASC). Since evidence is scarce, there are currently no evidence-based management guidelines for juvenile AIH. This survey was carried out amongst the paediatric members of the International AIH Group (IAIHG) to describe their practices in the management of JAILD.Methods An online survey questionnaire was distributed to members of the IAIHG with active practice (https://www.surveymonkey.de/r/Juvenile_AILD). The questionnaire consisted of four clinical scenarios on different presentations of AIH.Results Fifty-eight surveys were sent to the IAIHG members, out of which 43 (74%, 22 countries, four continents) were returned. None reported budesonide as a first-line induction agent for the acute presentation of AIH. Sixteen (37%) routinely perform liver biopsy at three years of biochemical remission. Thirty-five respondents (81%) perform magnetic resonance cholangiography (MRC) at presentation. Ciclosporin is the most widely used second-line agent (number of patients treated?=?~360, 21 centres). Mycophenolate mofetil (n?=?~225, 31 centres), tacrolimus (n?=?~130, 21 centres) and sirolimus (n?=?~5, 3 centres) are less often reported. Rescue therapy with infliximab and rituximab has been tried in eight centres (n?=?~19) and nine centres (n?=?~16), respectively.Conclusions Prednisolone remains the preferred first-line induction agent in JAILD. MRC at presentation is performed by the large majority of participants. Participants reported a wide variation in performing liver biopsy for therapy evaluation during follow-up. Within the paediatric members of the IAIHG there is considerable experience with second-line therapeutic agents.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results